ijms-logo

Journal Browser

Journal Browser

Molecular Research of Gastrointestinal Disease 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 801

Special Issue Editors


E-Mail Website
Guest Editor
1. Institute for Health and Sport, Victoria University, Melbourne 3011, Australia
2. Department of Medicine Western Health, University of Melbourne, Melbourne 3010, Australia
3. Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Sciences, Melbourne 3021, Australia
Interests: development of novel therapies for the treatment of enteric neuropathy; gut–brain axis; inflammatory bowel disease; colorectal cancer; gastrointestinal side effects of chemotherapy
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
1. Institute for Health and Sport, Victoria University, Melbourne 3011, Australia
2. Research and Ethics Department, Goulburn Valley Health, Shepparton 3630, Australia
3. School of Rural Health, La Trobe University, Mildura 3520, Australia
Interests: enteric nervous system; mesenchymal stem-cell-based treatments; inflammatory bowel disease; enteric neuropathy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent technological advances unravel many molecular, cellular, genetic, immunological, and microbiological aspects of the gastrointestinal tract functions in health and disease. These discoveries have important implications for a better understanding of basic mechanisms that maintain the physiological homeostasis of the gut. Malfunctioning of these fine-tuned molecular mechanisms leads to the onset and progression of gastrointestinal disorders. Understanding the molecular mechanisms and pathways is the turning point toward the development of novel diagnostic approaches and therapies for gastrointestinal disorders. Led by Prof Kulmira Nurgali and Dr Ainsley Robinson and assisted by our promotion editor, Dr Nyanbol Kuol (University of Nevada, Reno, US), this Special Issue of IJMS, “Molecular Research of Gastrointestinal Disease 2.0”, welcomes basic and clinical original research and review papers to be submitted for peer review. The submitted papers can cover any aspects of molecular research relevant to a broad range of gastrointestinal disorders.

Topics of interest include but are not limited to: 

  • molecular mechanisms of gastrointestinal functions in health and disease;
  • molecular targets for therapeutic intervention;
  • molecular markers for diagnostics of gastrointestinal disorders.

Dr. Kulmira Nurgali
Dr. Ainsley Robinson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal health
  • gastrointestinal disorders
  • gastrointestinal disease
  • gastrointestinal homeostasis
  • molecular targets
  • mechanisms
  • pathways
  • molecular markers
  • therapeutic targets

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

18 pages, 7117 KiB  
Article
Serotonin Transporter Deficiency Induces Metabolic Alterations in the Ileal Mucosa
by Nathan Calzadilla, Dulari Jayawardena, Aisha Qazi, Anchal Sharma, Kai Mongan, Shane Comiskey, Abhijith Eathara, Seema Saksena, Pradeep K. Dudeja, Waddah A. Alrefai and Ravinder K. Gill
Int. J. Mol. Sci. 2024, 25(8), 4459; https://doi.org/10.3390/ijms25084459 - 18 Apr 2024
Viewed by 364
Abstract
Serotonin transporter (SERT) deficiency has been implicated in metabolic syndrome, intestinal inflammation, and microbial dysbiosis. Interestingly, changes in microbiome metabolic capacity and several alterations in host gene expression, including lipid metabolism, were previously observed in SERT−/− mice ileal mucosa. However, the precise [...] Read more.
Serotonin transporter (SERT) deficiency has been implicated in metabolic syndrome, intestinal inflammation, and microbial dysbiosis. Interestingly, changes in microbiome metabolic capacity and several alterations in host gene expression, including lipid metabolism, were previously observed in SERT−/− mice ileal mucosa. However, the precise host or microbial metabolites altered by SERT deficiency that may contribute to the pleiotropic phenotype of SERT KO mice are not yet understood. This study investigated the hypothesis that SERT deficiency impacts lipid and microbial metabolite abundances in the ileal mucosa, where SERT is highly expressed. Ileal mucosal metabolomics was performed by Metabolon on wild-type (WT) and homozygous SERT knockout (KO) mice. Fluorescent-activated cell sorting (FACS) was utilized to measure immune cell populations in ileal lamina propria to assess immunomodulatory effects caused by SERT deficiency. SERT KO mice exhibited a unique ileal mucosal metabolomic signature, with the most differentially altered metabolites being lipids. Such changes included increased diacylglycerols and decreased monoacylglycerols in the ileal mucosa of SERT KO mice compared to WT mice. Further, the ileal mucosa of SERT KO mice exhibited several changes in microbial-related metabolites known to play roles in intestinal inflammation and insulin resistance. SERT KO mice also had a significant reduction in the abundance of ileal group 3 innate lymphoid cells (ILC3). In conclusion, SERT deficiency induces complex alterations in the ileal mucosal environment, indicating potential links between serotonergic signaling, gut microbiota, mucosal immunity, intestinal inflammation, and metabolic syndrome. Full article
(This article belongs to the Special Issue Molecular Research of Gastrointestinal Disease 2.0)
Show Figures

Figure 1

Other

Jump to: Research

8 pages, 522 KiB  
Case Report
Plexiform Fibromyxoma in the Stomach: Immunohistochemical Profile and Comprehensive Genetic Characterization
by Annabella Di Mauro, Rosalia Anna Rega, Maddalena Leongito, Vittorio Albino, Raffaele Palaia, Alberto Gualandi, Andrea Belli, Imma D’Arbitrio, Pasquale Moccia, Salvatore Tafuto, Annarosaria De Chiara, Alessandro Ottaiano and Gerardo Ferrara
Int. J. Mol. Sci. 2024, 25(9), 4847; https://doi.org/10.3390/ijms25094847 - 29 Apr 2024
Viewed by 171
Abstract
Plexiform fibromyxoma (PF), also referred to as plexiform angiomyxoid myofibroblast tumor, is an exceedingly rare mesenchymal neoplasm primarily affecting the stomach. Herein, we present a case of PF diagnosed in a 71-year-old male with a history of lung cancer, initially suspected to have [...] Read more.
Plexiform fibromyxoma (PF), also referred to as plexiform angiomyxoid myofibroblast tumor, is an exceedingly rare mesenchymal neoplasm primarily affecting the stomach. Herein, we present a case of PF diagnosed in a 71-year-old male with a history of lung cancer, initially suspected to have a gastrointestinal stromal tumor (GIST) of the stomach, who subsequently underwent subtotal gastrectomy. The histopathological and molecular features of the tumor, including mutations in ABL1, CCND1, CSF1R, FGFR4, KDR, and MALAT1-GLI1 fusion, are elucidated and discussed in the context of diagnostic, prognostic, and therapeutic considerations. Full article
(This article belongs to the Special Issue Molecular Research of Gastrointestinal Disease 2.0)
Back to TopTop